6Dunford JE,Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing BPs. J Pharmacol Exp Ther ,2001,296 (2) :235-242.
7Fleisch H. Pharmacodynamics of bisphosphonates. In: Fleisch H. Bisphosphonates in bone disease. Third edition. San Diego: Academic Press,2000.30- 60.
8Chesnut Ⅲ CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004,19 (8): 1241-1249.
9Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheuamatol, 2002,29(10) :2200-2208.
10Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003,42(6) :743-749.
